II. Mechanism

III. Indications

  1. Atrial Fibrillation Anticoagulation
  2. Deep Vein Thrombosis
    1. However, must be started concurrently with Heparin, unlike other Factor Xa Inhibitors (Apixiban, Rivaroxaban)

IV. Contraindications

  1. Creatinine Clearance <15 ml/min/1.73m2
  2. Creatinine Clearance >95 ml/min/1.73m2 (lower efficacy due to high drug clearance)
  3. Severe Cirrhosis (Child-Pugh Class C)

V. Dosing

  1. Standard dose: 60 mg orally daily
  2. Half dose indications (30 mg orally daily)
    1. Creatinine Clearance 15 to 50 ml/min/1.73m2 OR
    2. Weight <60 kg

VI. Pharmacokinetics

  1. Oral bioavailability: 62%
  2. Half-life: 10-14 hours
  3. Onset: 1-2 hours
  4. Renal clearance 50%

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Cost: Medications

savaysa (on 1/20/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
SAVAYSA 30 MG TABLET $9.34 each
SAVAYSA 60 MG TABLET $9.32 each

Ontology: edoxaban (C2975435)

Definition (NCI) An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C552171
English edoxaban, Edoxaban, Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, EDOXABAN